Incannex Healthcare (IXHL) news

Incannex announces first patient dosed in Dreamzz phase 2 study of IHL-42X

Incannex Healthcare Inc. (Nasdaq: IXHL) announced first patient dosed in DReAMzz Phase 2 crossover study of IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA). The study is designed to evaluate multiple ratios of the two active pharmaceutical…

Incannex receives additional A$5.1 million R&D tax incentive refund, completing more than A$11.2 million in non-dilutive capital received in 2026

Incannex Healthcare - receives final A$5.1 mln R&D tax incentive refund for FY25 - SEC filing

Incannex Healthcare Inc. (NASDAQ: IXHL) has received the final A$5.1 million in refunds under the Australian Government’s Research and Development Tax Incentive Program for fiscal year 2025, bringing the total non-dilutive funding received in 2026 to more than A$11.1 million. This follows an…

Algorae Pharmaceuticals Ltd-Nasdaq pharma chairman Troy Valentine joins Algorae board

Troy Valentine, Executive Director and co-founder of Alignment Capital Pty Ltd., has joined the board of Algorae Pharmaceuticals Ltd. as a director. Valentine brings extensive experience in finance and corporate governance, having previously served as Chairman of Incannex Healthcare , Inc., a role…

Incannex Healthcare - patent for IHL-42X expires July 9, 2040; extension possible after FDA approval - SEC filing

Incannex Healthcare Inc. (Nasdaq: IXHL) has disclosed in a recent SEC filing that the patent for its lead drug candidate, IHL-42X, is set to expire on July 9, 2040. The company noted that patent term extension may be possible following regulatory approval by the U.S. Food and Drug Administration…